Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.75 - $41.6 $754,215 - $1.77 Million
42,491 Added 21.47%
240,435 $9.53 Million
Q4 2023

Feb 13, 2024

BUY
$8.54 - $20.22 $1.12 Million - $2.66 Million
131,499 Added 197.91%
197,944 $3.77 Million
Q3 2023

May 14, 2024

SELL
$10.13 - $13.98 $1.33 Million - $1.84 Million
-131,499 Reduced 66.43%
66,445 $760,000
Q3 2023

Nov 14, 2023

BUY
$10.13 - $13.98 $108,087 - $149,166
10,670 Added 19.13%
66,445 $760,000
Q2 2023

May 14, 2024

BUY
$6.84 - $11.91 $170,439 - $296,773
24,918 Added 80.75%
55,775 $573,000
Q2 2023

Aug 14, 2023

BUY
$6.84 - $11.91 $170,439 - $296,773
24,918 Added 80.75%
55,775 $573,000
Q1 2023

May 14, 2024

BUY
$7.0 - $8.75 $2,576 - $3,220
368 Added 1.21%
30,857 $238,000
Q1 2023

May 11, 2023

BUY
$7.0 - $8.75 $2,576 - $3,220
368 Added 1.21%
30,857 $238,000
Q4 2022

May 14, 2024

BUY
$5.45 - $7.35 $35,697 - $48,142
6,550 Added 27.36%
30,489 $224,000
Q4 2022

Feb 13, 2023

BUY
$5.45 - $7.35 $35,697 - $48,142
6,550 Added 27.36%
30,489 $224,000
Q3 2022

May 14, 2024

SELL
$6.89 - $9.39 $130,751 - $178,194
-18,977 Reduced 44.22%
23,939 $172,000
Q3 2022

Nov 10, 2022

SELL
$6.89 - $9.39 $130,751 - $178,194
-18,977 Reduced 44.22%
23,939 $172,000
Q2 2022

May 14, 2024

SELL
$6.71 - $9.52 $1.04 Million - $1.48 Million
-155,028 Reduced 78.32%
42,916 $365,000
Q2 2022

Aug 15, 2022

BUY
$6.71 - $9.52 $134,642 - $191,028
20,066 Added 87.82%
42,916 $365,000
Q1 2022

May 16, 2022

BUY
$6.41 - $13.89 $60,709 - $131,552
9,471 Added 70.79%
22,850 $205,000
Q4 2021

Feb 14, 2022

BUY
$10.41 - $13.95 $139,275 - $186,637
13,379 New
13,379 $185,000

Others Institutions Holding ALPN

About ALPINE IMMUNE SCIENCES, INC.


  • Ticker ALPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,006,700
  • Description
  • Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...
More about ALPN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.